Table 1. Clinical characteristics of the study participants.
| Viremic Controllers [VCs, n = 07] | Viremic Non-Progressors [VNPs, n = 12] | Putative Progressors [PuPs, n = 11] | |
|---|---|---|---|
| Agea (Years), Range | 42 (29–60) | 39 (30–49) | 35 (21–59) |
| Gender | Female = 03 Male = 04 |
Female = 04 Male = 08 |
Female = 06 Male = 05 |
|
CD4+ T cell count
a
(cells/mm3), Range |
900 (501–1469) |
680 (501–910) |
553 (514–908) |
|
Viral Load
a,b
(log10 copies/ml) |
2.95 (1.73–3.04) |
4.73 (4.01–5.35) |
4.71 (3.58–5.98) |
| Duration of infectiona (Years), Range | 10 (8–24) |
10 (7–16) |
1 (0.5 – 03) |
| Antiretroviral therapy (ART) status | Naïve | Naïve | Naïve |
| HLA-B*27/B*57 status c | HLA-B*27 (+ve = 0/06) & HLA-B*57 (+ve = 1/07) |
HLA-B*27 (+ve = 1/09) & HLA-B*57 (+ve = 0/11) |
HLA-B*27 (+ve = 02/10) & HLA-B*57 (+ve = 1/11)d |
a
Data are expressed as the median (range).
b
Viral load was estimated at the time of sampling.
c
HLA-B*27 and HLA-B*57 allele status of 5 and 1 of the HIV-1 infected participants respectively, was not available due to lack of SSP-PCR amplification.
d
Only one participant was positive for both HLA-B*27 and HLA-B*57 allele.